Asia-Pacific private equity shows green shoots of recovery
India and Japan have become hotspots for PE investors
Deal value increased, exits recovered, fund-raising remained challenging, dry powder declined
SINGAPORE, March 24, 2025 /PRNewswire/ -- Despite another year of uncertain macroeconomic conditions, Asia-Pacific's private equity (PE) market is showing signs of recovery after two years of decline as deal value rose 11% to $176 billion in 2024, according to Bain & Company's Asia-Pacific Private Equity Report 2025 launched today. While the recovery is supported by moderate investments across the region, deal count declined 9% when compared with 2023.
Overall, Asia-Pacific deals were larger. Average deal size in the region rose to $133 million, up 22% over 2023 and 12% higher than the previous five-year (2019-2023) average. The number of megadeals, or deals valued at $1 billion or more, increased by 50% compared to 2023, lifting average deal size.
Buyouts continued to be in favor as they accounted for over half of 2024's total deal value. Notably, the share of buyout deals rose in traditionally growth deal markets, including India, Southeast Asia, and Greater China. Lower interest rates across most of the region also fueled more buyouts.
In 2024, carve-out deals totaled 19% of all buyouts over $100 million. Despite lower average returns, 44% of Asia-Pacific general partners (GPs) surveyed by Bain consider carve-outs a top investment opportunity, possibly due to immense opportunities in Japan and Korea when conglomerates rationalize operations and sell off business units.
"Investors are still wary of market uncertainty and so we continue to see them favoring buyouts as a way for greater control to manage risks and ensure a clear path to increase value. For those looking at carve-outs, it is essential to have an actionable value creation plan," said Sebastien Lamy, co-head of Bain & Company's Asia-Pacific PE practice.
"And while most markets in Asia-Pacific saw deal value rising in 2024, the actual dealmaking activity varied widely across the region. India and Japan are looking to be hotspots as their active investor pools have risen and major global PE funds are planning to deploy more capital in these markets."
Greater China continued to lead with the highest deal value in the region, but deal value only rose modestly compared to 2023, and its share of the market continued to drop accounting for 27% of the region's total deal value in 2024. India was Asia-Pacific's top performer, with deal value and count rising. The market remains one of the fastest growing in the region based on GDP, and investors are drawn to its strong growth fundamentals. Australia–New Zealand's deal value more than doubled, fueled by the $16 billion AirTrunk deal. Japan's deal count was unchanged, but deal value was down sharply vs. the previous year, which included multiple megadeals. In South Korea and Southeast Asia, dealmaking revived, with gains in deal value.
Some of the largest global fund managers with over two decades of investment experience in Asia-Pacific PE are shifting their focus away from China. Last year, these GPs closed almost twice as many deals in Japan and India compared to the average from 2014 to 2018. Their investments in Greater China, by contrast, declined to less than one-third of the same period. Looking forward, major global PE funds plan to deploy more capital in India and Japan.
Similarly, limited partners (LPs) recognize the attractiveness of India and Japan and endorse the strategic shift to those markets. In Preqin's 2024 global LP survey, Japan ranked No. 4 globally for the best PE investment opportunities in developed markets (after the US, Western Europe, and the UK)—and among emerging markets, India ranked No. 1 globally.
Looking at industries, while technology continued to lead with the highest share of deal value and count across the region, its share of deal value shrank to 25% in 2024, down from 50% in 2018, as GPs sought greater diversity in their portfolios in an uncertain environment. Investments in communications and financial services showed the highest growth rates in deal value over the previous year, powered by several large deals in data centers, and sizable deals in property loan and personal loan businesses in India.
The challenging private equity environment in Asia-Pacific is squeezing out bottom-ranked investors. In 2024, the number of active investors declined 10%—the second drop in two years. In contrast, the top 20 investors' share of total deal value remained high at 41%. Japan and India are proving to be attractive markets for PE investors as the number of active investors in Japan rose 14% in 2024, bucking a regional trend of shrinking competition, while in India, active investors rose 29%, helping fuel an increase in deal count and deal value. Global investment firms are also setting up offices in these two markets.
Deal multiples—the ratio of enterprise value to EBIDTA—edged up to 12.8 from 10.3 a year earlier due to rising valuations of comparable companies listed on public markets across the region and public market recoveries or rallies.
Most markets saw some improvement in exit value and count in 2024, with India being the region's largest exit market in terms of value and count, supported by a vibrant IPO market. Due to a sharp decline in China's exit market – partly driven by Greater China's weak stock market performance - total exit value and count for the region were roughly flat, ending two years of precipitous decline.
For the third consecutive year, investors raising new funds (excluding RMB funds) continued to face significant challenges. The value of Asia-Pacific-focused funds raised in 2024 slumped to a 10-year low of $74 billion, down more than 20% year on year, and 43% lower than the previous five-year average. Global fund-raising in 2024 was down 23%, excluding RMB funds, and Asia-Pacific's share of global fund-raising was a low 7%, down from 13% in 2021.
Dry powder, or total unspent PE capital, declined for the Asia-Pacific region from its record level in 2023. A challenging fund-raising environment contributed to the dip.
"Green shoots are appearing in Asia-Pacific's PE market and despite ongoing challenges and a still uncertain macro environment, fund managers are more optimistic about 2025," said Prabhav Addepalli, a Bain & Company PE partner, based in New Delhi. "The region's fund managers have mixed expectations on future returns, but our survey highlighted a noticeable optimism, with 87% of respondents stating they believe returns will not decrease in the coming three to five years, up from 61% in 2023."
Media contact: Ann Lee - ann.lee@bain.com
About Bain & Company
Bain & Company is a global consultancy that helps the world's most ambitious change makers define the future.
Across 65 cities in 40 countries, we work alongside our clients as one team with a shared ambition to achieve extraordinary results, outperform the competition, and redefine industries. We complement our tailored, integrated expertise with a vibrant ecosystem of digital innovators to deliver better, faster, and more enduring outcomes. Our 10-year commitment to invest more than $1 billion in pro bono services brings our talent, expertise, and insight to organizations tackling today's urgent challenges in education, racial equity, social justice, economic development, and the environment. We earned a platinum rating from EcoVadis, the leading platform for environmental, social, and ethical performance ratings for global supply chains, putting us in the top 1% of all companies. Since our founding in 1973, we have measured our success by the success of our clients, and we proudly maintain the highest level of client advocacy in the industry.
View original content to download multimedia:https://www.prnewswire.com/news-releases/asia-pacific-private-equity-shows-green-shoots-of-recovery-302409146.html
SOURCE Bain & Company

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Sport Clips Haircuts Hosts National Signing Days
Recruiting Top Styling Talent Ready for the Big Leagues GEORGETOWN, Texas, June 14, 2025 /PRNewswire/ -- Styling professionals looking to take their careers to the next level will get to swing big when Sport Clips Haircuts hosts its annual National Signing Days on June 17 and 18 at participating locations. Much like a draft day for the beauty industry, this two-day event offers guaranteed interviews, same-day job offers for qualified candidates, and a chance to join a team known for developing all-star talent. Known as the leading haircare provider for men and boys, Sport Clips is calling on licensed stylists and barbers ready to bring their A-game to a high-performance environment. With top-tier training programs, a team-first culture, and a track record of promoting from within, Sport Clips is scouting professionals ready to make a strong play for their future. "National Signing Days are about more than filling positions behind the chairs—they're about finding team members who want to grow, thrive, and succeed," said Julie Vargas, a licensed stylist who has grown her career to become Sport Clips Haircuts' vice president of career opportunities. "We provide the support and structure to help stylists advance their careers, and we're proud to welcome the next wave of talent during this event." Sport Clips locations across the country will open their doors for on-the-spot interviews and instant offers. Stylists will also be entered for a chance to win a $100 Amazon gift card, which will be distributed to the winners after the event. Appointments are available Tuesday, June 17, from 4 - 7 p.m. local time and Wednesday, June 18, from noon - 3 p.m. local time. Interested professionals can register online to secure their spot and get ready to join a winning team. About Sport Clips HaircutsSport Clips Haircuts is the nation's leading men's and boys' hair care franchise with almost 1,900 locations open in the U.S. and Canada. Fully equipped for the sports enthusiast, Sport Clips surrounds its clients with televisions tuned to sports and sports-themed decor. Stylists are trained to be the pros in men's hair and enjoy a fun work environment with a guaranteed base-pay plus service commission, retail commission and tips. Sport Clips also supports the growth of its team members through continuing education, exciting contests, and award recognition. Sport Clips was recognized in 2025 as a "Best Company for Women" by Comparably. Through the Eric Gozur-Wayne McGlone Memorial Relief Fund, Sport Clips aids employees facing emergent financial situations. Sport Clips also provides "Haircuts with Heart" through its annual Help A Hero fundraiser that has donated $15 million to the VFW; national partnership with St. Baldrick's Foundation, the largest private funder of childhood cancer research grants; and other national and local philanthropic outreach. To learn more about Sport Clips and career opportunities near you, visit View original content to download multimedia: SOURCE Sport Clips Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in the 180mg cohort achieved a clinical response Tryptase levels below the lower limit of quantification observed in 10 of 12 participants (83%) No serious adverse events and no grade 3 or higher adverse events reported in the 180mg cohort Company to host conference call and webinar on Monday, June 16, at 8:00 a.m. EDT REDWOOD CITY, Calif., June 14, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, is presenting data from the 180mg cohort of the Company's SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adult participants with CIndU at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress. Briquilimab (subcutaneous) administration resulted in deep disease control at 180mg, with 12 of 12 participants (100%) enrolled in the cohort achieving a clinical response within the 8-week preliminary analysis period. The efficacy observed was rapid and durable, with 8 of 12 participants (66%) achieving clinical response by week 2, and 7 of 12 participants (58%) maintaining clinical response through week 8. Briquilimab continued to be well tolerated in the study, with no serious adverse events (SAEs) and no grade 3 or higher adverse events (AEs) reported in the 180mg cohort. 'We are very pleased by the updated results from the SPOTLIGHT study, with briquilimab driving complete responses in over 90% of CIndU participants enrolled in the 180mg cohort,' said Ronald Martell, President and Chief Executive Officer of Jasper. 'In addition to the responses observed, we are pleased that briquilimab continued to be well tolerated in the study. Taken together with the results observed thus far in the BEACON study in CSU, these data demonstrate the ability of briquilimab to support optimal biologic dosing by rapidly delivering robust and durable control of urticaria symptoms, along with a potentially differentiated safety profile. On behalf of the entire Jasper team, I'd like to thank both the investigators and the patients who participated in SPOTLIGHT, along with their families and caregivers.' SPOTLIGHT Study Design and Data Summary: The SPOTLIGHT study is a Phase 1b/2a open label clinical trial evaluating a single dose of subcutaneous briquilimab in adult participants with cold urticaria (ColdU) or symptomatic dermographism (SD), the two most prevalent sub types of CIndU, who are refractory to antihistamines. The study enrolled 27 participants across three dose cohorts, 40mg (n=3), 120mg (n=12), and 180mg (n=12). The primary endpoints are safety and tolerability of briquilimab and secondary endpoints are focused on clinical activity and PK/PD, including measurement of serum tryptase. Among the 12 participants enrolled in the 180mg cohort, 3 were diagnosed with ColdU (25%) and 9 with SD (75%). Participants had high disease burden as assessed by provocation threshold testing. In the 180mg cohort, mean baseline TempTest® threshold was 18.7°C (range: 10-26°C) for ColdU participants, and mean baseline FricTest® threshold was 3.7 of 4 (range: 3-4) for SD participants. 12 of 12 participants (100%) enrolled in the 180mg dose cohort achieved a clinical response to provocation testing within the 8-week preliminary analysis period following treatment. 11 of 12 participants (92%) treated in the cohort achieved a complete response (CR) with either their critical temperature threshold improving to at least 4°C for ColdU participants or their FricTest® score improving to 0 for SD participants, and 1 of 12 participants achieved a partial response (PR) as their best response. Complete responses in TempTest® or FricTest® were observed as early as 1 week following dosing in the 180mg cohort, with 8 of 12 participants (66%) achieving CR or PR by week 2. Overall, 22 of 27 participants (81%) enrolled in the study achieved a CR and 26 of 27 participants (96%) achieved a CR or PR. Briquilimab40mg(n=3) Briquilimab120mg(n=12) Briquilimab180mg(n=12) BriquilimabAll doses (n=27) Complete Response, n (%) 1 (33.3%) 10 (83.3%) 11 (91.6%) 22 (81.5%) ColdU, n 0 3 3 6 Symptomatic Dermographism, n 1 7 8 16 Partial Response, n (%) 2 (66.7%) 1 (8.3%) 1 (8.4%) 4 (14.8%) ColdU, n 1 0 0 1 Symptomatic Dermographism, n 1 1 1 3 Complete or Partial Response at any time, n (%) 3 (100%) 11 (91.6%) 12 (100%) 26 (96.3%) At the 8-week timepoint following treatment, 7 of 12 (58%) participants in the 180mg cohort maintained an ongoing clinical response, with 5 participants achieving CR and 2 participants achieving PR. Mean baseline serum tryptase for participants in the 180mg cohort was 5.1 ng/ml (standard deviation: 2.29 ng/ml). Significant reductions in tryptase were observed as early as the week 1 assessment and were correlated with the onset of clinical responses. Tryptase measurements below the lower limit of quantification were observed in 10 of 12 participants (83%) in the 180mg cohort. Briquilimab was well tolerated in the study. No SAEs or AEs ≥ grade 3 were reported in the 180mg cohort. Furthermore, there were no reported AEs related to hair or skin color changes. 2 of 12 participants (17%) enrolled in the 180mg cohort experienced taste change/hypogeusia. Mild, transient drops in neutrophil counts were observed, with 6 of 12 participants (50%) experiencing grade 1 or grade 2 neutrophil count decreases which resolved in a median of 16 days. 5 of the 6 participants who experienced neutrophil count decreases were diagnosed with concurrent viral infections that may have contributed to observed decreases. 'It is exciting to see additional clinical data showing that treatment with briquilimab can lead to deep clinical benefit shortly after administration in a difficult-to-treat antihistamine refractory CIndU patient population,' said Martin Metz, M.D., Professor of Dermatology and Allergy Charité – Universitätsmedizin Berlin. 'Notably, the safety and tolerability results observed in both the SPOTLIGHT and BEACON studies thus far show that the adverse events possibly caused by briquilimab are mostly low frequency, low grade, and resolve quickly. Patients with CIndU currently have very few treatment options, and I look forward to continuing to support the development of novel therapeutics to treat this debilitating disease.' Conference Call / Webinar Jasper will host a conference call and webinar on Monday, June 16, 2025, at 8:00 a.m. EDT. A live question and answer session with management will follow the formal presentations. A link to the webinar, including presentation slides, can be found here. To access the live conference call via phone, dial 1-844-826-3033 from the US or 1-412-317-5185 from outside the US, or click here. The conference ID is 10200147, and the conference call passcode is 6392607. The presentation slides and a link to the live and archived webinar will also be available on the Events & News – Events page of Jasper's Investor Relations website. About Jasper Jasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor KIT, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria and asthma. Jasper is currently conducting clinical studies of briquilimab as a treatment in patients with CSU, CIndU or asthma. Briquilimab has a demonstrated efficacy and safety profile in patients and healthy volunteers, with positive clinical outcomes in CSU and CIndU. For more information, please visit us at Forward-Looking Statements Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'should,' 'would,' 'plan,' 'predict,' 'potential,' 'seem,' 'seek,' 'future,' 'outlook' and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab's potential, including with respect to its potential in mast cell driven diseases such as CSU, CIndU, and asthma; briquilimab's ability to support optimal biologic dosing by rapidly delivering robust and durable control of urticaria symptoms along with a potentially differentiated safety profile; and the potential for treatment with briquilimab to lead to deep clinical benefit shortly after administration in a difficult-to-treat antihistamine refractory CIndU patient population. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that prior test, study and trial results may not be replicated in continuing or future studies and trials; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper's product candidates may not be beneficial to patients or successfully commercialized; patients' willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper's business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper's business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper's assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contacts: Alex Gray (investors) Jasper Therapeutics 650-549-1454 agray@ Joyce Allaire (investors) LifeSci Advisors 617-435-6602 jallaire@ Lauren Walker (media) Real Chemistry 646-564-2156 lbarbiero@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Sturm Ruger CEO sees 2025 bottom line impacted by price repositioning moves
On June 13, Sturm, Ruger & Company provided a communication from Todd Seyfert, CEO, to its employees regarding his first 100 days and management's ongoing corporate strategy initiatives, the company disclosed in a regulatory filing. In the letter to employees, Seyfert stated in part: 'The last few months have been nothing short of transformative – and it's thanks to your focus, dedication, and belief in what we're building. As I have been doing since my first days as CEO, I wanted to update you all transparently and clearly about where I see our short-term and long-term future… With these bold moves, there comes a cost – both emotionally and financially. Change of this scale requires tough decisions, meaningful investment, and short-term impacts that we've chosen to take head-on to position Ruger for long-term strength… It is important to note that we are making these strategic decisions now – thoughtfully and intentionally – so that Ruger is positioned for consistency, stability, and profitable growth in 2026 and beyond. Yet, there will be a cost to the Company for 2025. We expect the expense-related to these initiatives to total approximately $15 million to $20 million over the remainder of the year. We additionally anticipate our price repositioning moves to impact our overall bottom line over that same period. Consequently, we currently believe that our results for the remainder of the year, before the one-time costs and expenses, will look more like prior periods, such as the latter part of 2019, where the Company continued to focus on executing its long-term strategy and delivering long-term value for shareholders in the face of broader industry challenges. These actions will be largely completed by the beginning of 2026, placing Ruger in a strong position for renewed growth and performance in the years to come. Importantly, none of this will slow our momentum when it comes to investing in what matters most, including aggressive new product development and expansion of capacity in areas where market demand exceeds our current ability to supply. We remain fully committed to profitable expansion, product innovation, agile responsiveness, and ensuring we meet the expectations of our customers and the marketplace.' Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on RGR: Disclaimer & DisclosureReport an Issue Sturm Ruger Announces Strategic Initiatives Under New CEO Supreme Court blocks Mexico suit against gunmakers Sturm Ruger Appoints New General Counsel Sturm Ruger Amends By-Laws for Shareholder Actions Sturm Ruger Reports Stable Q1 2025 Financial Results Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data